Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Marre, M. ; Shaw, J. ; Brändle, M. ; Bebakar, W. M. W. ; Kamaruddin, N. A. ; Strand, J. ; Zdravkovic, M. ; Le Thi, T. D. ; Colagiuri, S.
Diabetic medicine, 2009-03, Vol.26 (3), p.268-278 [Periódico revisado por pares]Oxford, UK: Blackwell Publishing Ltd
Texto completo disponível